{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-042709","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.065341+00:00","generated_at":"2026-06-07T21:25:46.445442+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InspireMD announces EFS agreement with Jacobs Institute for CGuard EPS in tandem lesion stroke patients","bullets":["Agreement with Jacobs Institute to execute an Early Feasibility Study (EFS) of CGuard EPS for acute stroke with tandem lesions.","EFS to enroll 15 patients across 3 U.S. sites; no FDA-approved stents currently exist for this indication.","CGuard EPS features MicroNet mesh covering for embolic protection, low metal surface area to reduce thrombotic risk.","CEO Marvin Slosman states tandem lesion indication is a critical component of long-term growth strategy.","Dr. Siddiqui notes ~20% of acute strokes are tandem, and stenting in conjunction with thrombectomy may be superior."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-042709","json":"https://secwatch.observer/filing/0001493152-23-042709.json","markdown":"https://secwatch.observer/filing/0001493152-23-042709.md","text":"https://secwatch.observer/filing/0001493152-23-042709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223042709/0001493152-23-042709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223042709/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:25:46.445442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}